Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Tenaya Therapeutics Inc

TNYA ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.73

▼ -0.67%

Market Cap $163.26M · Vol 167.43K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$163.26M

Micro Cap

Div Yield

N/A

EPS Growth

+28.33%

YoY

RSI (14)

41.96

Momentum

Beta

2.77

vs Market

52W High

$2.35

69.02% below

52W Low

$0.53

36.78% above

Volume

167.43K

Avg 326.73K

P/B

1.25

Price-to-book

ROE

-83.84%

Return on equity

Free Float

99.34%

Public shares

Shariah Compliance8 STANDARDS

✗ Tenaya Therapeutics Inc (TNYA) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TNYA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.18%

-15.79%

-22.13%

+10.32%

YTD

+2.33%

-23.11%

-81.38%

-96.83%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-90,597,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-83.84%
ROA · ROIC	-67.90% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.25
P/FCF	N/A
EPS Growth	+28.33%
Outstanding Shares	224.23M

Technical Indicators

50-Day SMA	$0.76
200-Day SMA	$0.85
RSI (14)	41.96
Beta	2.77
52-Week High	$2.35
52-Week Low	$0.53

Volume Today	167.43K
Avg Daily Volume (30D)	326.73K
Relative Volume	0.51x
Volatility (10D)	55.47
Volatility (30D)	55.37
Free Float	99.34%

Analyst Consensus

BUY

Current Price $0.73

Mean Target $9.33

52W Low$0.53 52W High$2.35

Current

Target

$0.53 $2.35

Current Analyst target

+1,181.87% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00FPMK2T2

ISINUS87990A1060

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.